These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33097949)

  • 1. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
    Goel A; Bhadauria DS; Kaul A; Verma A; Tiwari P; Rungta S; Rai P; Gupta A; Aggarwal R
    Nephrol Dial Transplant; 2021 Sep; 36(10):1867-1871. PubMed ID: 33097949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis.
    Bhat MA; Mir AN; Parry MA; Parray IA
    Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):570-575. PubMed ID: 38725207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
    N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
    Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
    Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
    Singh A; Kumari S; Kumar P; De A; Singh V
    J Viral Hepat; 2018 Dec; 25(12):1501-1506. PubMed ID: 30113115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
    Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
    J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
    Li C; Hu J
    Medicine (Baltimore); 2018 Apr; 97(15):e0416. PubMed ID: 29642211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
    Merat S;
    Clin Infect Dis; 2020 May; 70(10):2206-2212. PubMed ID: 31504303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
    Smith MA; Regal RE; Mohammad RA
    Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
    de Lédinghen V; Lusivika-Nzinga C; Bronowicki JP; Zoulim F; Larrey D; Metivier S; Tran A; Marcellin P; Samuel D; Chazouillères O; Chevaliez S; Dorival C; Fontaine H; Pawlotsky JM; Carrat F; Pol S;
    J Viral Hepat; 2020 Oct; 27(10):964-973. PubMed ID: 32436335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
    Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
    Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
    Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients.
    Hussain N; Farooq N; Maqsood M; Rajoka MSR; Bilal M
    Arch Microbiol; 2021 Jul; 203(5):2365-2371. PubMed ID: 33660021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
    BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.
    Teegen EM; Globke B; Schott E; Pratschke J; Eurich D
    Exp Clin Transplant; 2018 Feb; 16(1):61-67. PubMed ID: 29137590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes.
    Rossato G; Tovo CV; Almeida PRL
    Braz J Infect Dis; 2020; 24(1):25-29. PubMed ID: 31760038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.